Avience Biomedicals Limited
Bookbuilding IPO · NSE
- Price band
- ₹196 - ₹208
- Lot size
- 600 shares
- Issue amount
- ₹30.24 cr
- Total subscription
- 385.4×
- Opens
- 18 Jun 2026
- Closes
- 22 Jun 2026
- Allotment
- 23 Jun 2026
- Listing
- 25 Jun 2026
Offer at a glance
Issue overview
- Issue size
- 14,53,800 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,17,600
- Fresh issue
- ₹30.24 cr
- Offer for sale
- ₹0 cr
- Registrar
- Skyline Financial Services Private Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,24,800
- Issue type
- Bookbuilding IPO
- Shares before issue
- 40,31,256
- Shares after issue
- 54,85,056
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 1,200 | ₹2,49,600 |
| sHNI | 3 | 1,800 | ₹3,74,400 |
| bHNI | 9 | 5,400 | ₹11,23,200 |
Share reservation
Subscription & GMP
Subscription by category
Reported 22 Jun 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 172 |
| NIB | 0 | 31,836 |
| RETAIL | 401 | 1,60,944 |
| HNIs(10L +) | 77 | 16,492 |
| HNIs (2-10L) | 38 | 15,344 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 5.69 | 1,119.82 |
| FIIs | 0 | 195.21 |
| FIs | 0 | 139.51 |
| Mutual Funds | 0 | 18.7 |
| Others | 0 | 766.4 |
| RETAIL | 10.01 | 4,017.16 |
| HNIs 2+ | 1.44 | 647.77 |
| HNIs 10+ | 2.87 | 1,925.39 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 14.24 | 19.06 | 6.52 |
| ROE | 22.38 | 49.89 | 34.47 |
| ROCE | 16.99 | 24.88 | 17.97 |
| RONW | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 11.59 | 0 |
| POST IPO(PE) | 16.56 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, and export of molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) sectors. The company offers a wide range of healthcare products, including rapid test kits, molecular diagnostic kits, biochemistry and hematology analyzers, medical devices, and diagnostic reagents. Its products serve pathology laboratories, hospitals, microbiology labs, and research centers in India and overseas. Along with manufacturing, the company also operates as a distributor and trader of medical equipment. Its manufacturing facility is located in Noida, Uttar Pradesh. As of January 31, 2026, Avience Biomedicals had 75 permanent employees and 33 contractual employees.
Strengths
- Diversified Diagnostic Product Portfolio: Offers rapid test kits, analyzers, molecular diagnostics, and medical devices across multiple healthcare segments.
- Strong Distribution Network & Market Reach: Presence across India with growing international footprint supports business expansion.
- Quality-Focused Operations: ISO-certified processes and regulatory compliance enhance product reliability and customer trust.
Risk factors
- Limited Operating History: Recently incorporated company with a relatively short track record.
- Regulatory Compliance Risk: Medical devices and diagnostic products are subject to stringent approvals and regulations.
- Dependence on Healthcare Industry Demand: Growth depends on spending by hospitals, laboratories, and healthcare institutions.
Promoters
Mr. Dharam Deo Choudhary
Mr. Ram Nagina Choudhary
Mr. Janardan Pal
Ms. Deepa Choudhary
Registrar & documents
Lead manager
Fintellectual Corporate Advisors Private Limited
Registrar & contacts
Skyline Financial Services Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
C-11, Block-C Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
1800-12-04-636
[email protected]Company website ↗Understanding AVIENCE IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.